These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 22256871)

  • 1. Pharmacogenetics of drugs withdrawn from the market.
    Zhang W; Roederer MW; Chen WQ; Fan L; Zhou HH
    Pharmacogenomics; 2012 Jan; 13(2):223-31. PubMed ID: 22256871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can pharmacogenetics help rescue drugs withdrawn from the market?
    Shah RR
    Pharmacogenomics; 2006 Sep; 7(6):889-908. PubMed ID: 16981848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WITHDRAWN--a resource for withdrawn and discontinued drugs.
    Siramshetty VB; Nickel J; Omieczynski C; Gohlke BO; Drwal MN; Preissner R
    Nucleic Acids Res; 2016 Jan; 44(D1):D1080-6. PubMed ID: 26553801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacogenetics and prediction of side effects of drugs].
    Harrak M; Khabbal Y; Amarti A; El Hassouni M; Ouldim K
    Ann Biol Clin (Paris); 2014; 72(4):405-12. PubMed ID: 25119798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system.
    Ingelman-Sundberg M; Sim SC
    Biochem Biophys Res Commun; 2010 May; 396(1):90-4. PubMed ID: 20494117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
    Roses AD
    Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacogeneticist's look at drug effects and the drug development process: an overview.
    Kalow W
    Expert Opin Pharmacother; 2005 Jul; 6(8):1299-303. PubMed ID: 16013980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency.
    Linder MW; Prough RA; Valdes R
    Clin Chem; 1997 Feb; 43(2):254-66. PubMed ID: 9023127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating a newly developed pharmacogenetic array: screening in a Spanish population.
    Almoguera B; Riveiro-Alvarez R; Gomez-Dominguez B; Lopez-Rodriguez R; Dorado P; Vaquero-Lorenzo C; Dal-Ré R; Fernandez-Piqueras J; Llerena A; Abad-Santos F; Ayuso C
    Pharmacogenomics; 2010 Nov; 11(11):1619-25. PubMed ID: 21121779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic issues in thorough QT trials.
    Judson RS; Salisbury BA; Reed CR; Ackerman MJ
    Mol Diagn Ther; 2006; 10(3):153-62. PubMed ID: 16771601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics: has it reached the clinic?
    Schwartz JB
    J Gend Specif Med; 2002; 5(2):13-8. PubMed ID: 11974670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics and adverse drug reactions.
    Meyer UA
    Lancet; 2000 Nov; 356(9242):1667-71. PubMed ID: 11089838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Principles in pharmacogenetics.
    Roden DM
    Epilepsia; 2001; 42 Suppl 5():44-8. PubMed ID: 11887967
    [No Abstract]   [Full Text] [Related]  

  • 14. The hunt for new genes and polymorphisms that can control the response to drugs.
    Sheffield LJ
    Pharmacogenomics; 2002 Sep; 3(5):679-86. PubMed ID: 12223052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PharmVar GeneFocus: CYP2D6.
    Nofziger C; Turner AJ; Sangkuhl K; Whirl-Carrillo M; Agúndez JAG; Black JL; Dunnenberger HM; Ruano G; Kennedy MA; Phillips MS; Hachad H; Klein TE; Gaedigk A
    Clin Pharmacol Ther; 2020 Jan; 107(1):154-170. PubMed ID: 31544239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics and the concept of individualized medicine.
    Shastry BS
    Pharmacogenomics J; 2006; 6(1):16-21. PubMed ID: 16302022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome p450 part 2: what nurses need to know about the cytochrome p450 family systems.
    Krau SD
    Nurs Clin North Am; 2013 Dec; 48(4):681-96. PubMed ID: 24295195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Xenobiotic-metabolizing polymorphic enzymes. An opportunity for individualized drug treatment].
    Lhermitte M; Allorge D; Broly F
    Bull Acad Natl Med; 2006 Jan; 190(1):55-69; discussion 69-73. PubMed ID: 16878446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetics/genomics and drug effects.
    Heller F
    Acta Clin Belg; 2013; 68(2):77-80. PubMed ID: 23967712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.